about
Clinical and economic impact of non-adherence in COPD: a systematic reviewSystematic Review and Quality Appraisal of Cost-Effectiveness Analyses of Pharmacologic Maintenance Treatment for Chronic Obstructive Pulmonary Disease: Methodological Considerations and RecommendationsEffectiveness and success factors of educational inhaler technique interventions in asthma & COPD patients: a systematic review.Towards tailored and targeted adherence assessment to optimise asthma management.Does co-payment for inhaler devices affect therapy adherence and disease outcomes? A historical, matched cohort study.Improving inhaler adherence in patients with chronic obstructive pulmonary disease: a cost-effectiveness analysis.Impact of multiple-dose versus single-dose inhaler devices on COPD patients' persistence with long-acting β₂-agonists: a dispensing database analysisPredictors of cost-effectiveness of selected COPD treatments in primary care: UNLOCK study protocol.Enhancing the use of Asthma and COPD Assessment Tools in Balearic Primary Care (ACATIB): a region-wide cluster-controlled implementation trial.Cost-effectiveness and budget impact of the fixed-dose dual bronchodilator combination tiotropium-olodaterol for patients with COPD in the Netherlands.Cost comparison of asthma treatments in 12-week study: caution about matching and short observational follow-up.Optimizing identification and management of COPD patients - reviewing the role of the community pharmacist.Associations between chronic comorbidity and exacerbation risk in primary care patients with COPD.Medication monitoring and optimization: a targeted pharmacist program for effective and cost-effective improvement of chronic therapy adherence.What We Mean When We Talk About Adherence in Respiratory Medicine.Enhancing Respiratory Medication Adherence: The Role of Health Care Professionals and Cost-Effectiveness Considerations.Clinical characteristics, treatment patterns, and socio-economic burden of COPD in Bulgaria.Factors associated with inhaled corticosteroids prescription in primary care patients with COPD: A cross-sectional study in the Balearic Islands (Spain).Comorbidome, Pattern, and Impact of Asthma-COPD Overlap Syndrome in Real Life.Investigating the association between medication adherence and health-related quality of life in COPD: Methodological challenges when using a proxy measure of adherence.Higher Adherence During Reimbursement of Pharmacological Smoking Cessation Treatments.Mapping the clinical chronic obstructive pulmonary disease questionnaire onto generic preference-based EQ-5D values.Hollywood raising awareness of smoking-related diseases: can it proactively counteract the impact of smoking in movies?-the final mission of Star Trek's Mr Spock.Proactive pharmaceutical care interventions improve patients' adherence to lipid-lowering medication.Asthma Cost-Effectiveness Analyses: Are We Using the Recommended Outcomes in Estimating Value?Addressing the Impact and Unmet Needs of Nonadherence in Asthma and Chronic Obstructive Pulmonary Disease: Where Do We Go From Here?Urging Europe to put non-adherence to inhaled respiratory medication higher on the policy agenda: a report from the First European Congress on Adherence to Therapy.Effects of targeting disease and medication management interventions towards patients with COPD.Improving adherence to lipid-lowering therapy in a community pharmacy intervention program: a cost-effectiveness analysis.Availability, use, and affordability of medicines in urban China under universal health coverage: an empirical study in Hangzhou and Baoji.HbA1c response after insulin initiation in patients with type 2 diabetes in real-life: identifying distinct subgroups.Personalising adherence-enhancing interventions using a smart inhaler in patients with COPD: an exploratory cost-effectiveness analysis.An international perspective on hospitalized patients with viral community-acquired pneumoniaACO: Time to move from the description of different phenotypes to the treatable traitsReal‐life effectiveness of inhaler device switch from dry powder inhalers to pressurized metred‐dose inhalers in patients with asthma treated with ICS/LABADiabetes mellitus comorbidity in patients enrolled in tuberculosis drug efficacy trials around the world: A systematic reviewMaking sense of cost-effectiveness analyses in respiratory medicine: a practical guide for non-health economistsHigh COPD prevalence at high altitude: does household air pollution play a role?Development of the International Severe Asthma Registry (ISAR): A Modified Delphi StudyCost-Effectiveness of Biological Asthma Treatments: A Systematic Review and Recommendations for Future Economic Evaluations
P50
Q26852247-7BEF8AAB-72AE-432A-B374-88A881BCDBB7Q30245662-00EE03C7-34DB-435E-B244-359A85CD9EE9Q30356010-4442CCF9-BAD4-4523-8BE4-3C56D0E359F3Q30400460-8DC37B4E-A13B-405F-91CE-5E635958ACD3Q33597458-A487C990-1EEF-47FA-A2FB-B88E274980D0Q33794408-67724F96-68C4-4AB0-88E9-E9D351BDEA16Q35216376-A1C526D3-A818-452B-B476-C963DE11FF93Q35923308-ADF847E6-B4A0-4452-BA92-F76A63BA6F9EQ36671060-0F32760F-85E1-4308-900E-A7B22EC38A76Q37283438-370B10F6-5977-4159-96D2-C1D2F6EDDB30Q37387365-B5092CC5-B110-48F3-9BB9-FB2B6C72F31BQ37579554-E49D815E-5DF1-4575-82BB-5C679B432A46Q37628063-009C302B-27FB-4146-9FFA-10489F117655Q38233931-B27D2D3C-24E8-46C4-8F4D-5E520302AF3CQ38825123-EE882A41-CF0D-4280-B57D-BC5EC5E5772DQ38944504-81D3B70D-C9BD-4F8D-A1EB-808AD341206FQ39036752-13226713-5868-43C0-9C8A-28783045AC93Q39420903-DC13B781-20AA-4F46-B334-1F7DE51AF0E5Q40031479-9650389E-1D76-4128-BD6F-456D453CE414Q40240625-533E7B7E-64AD-4E9E-892D-925B7DA2AF87Q41202699-ADEBF36E-B083-4343-9712-5BC79985ABB2Q41216295-EF23C290-F242-4D6F-8D06-FBE44F64B3BAQ42366776-632A3151-954D-4B3A-A93A-804412C902DEQ45913960-FAFC9815-8EB7-4944-8C98-8177A73818A4Q47255212-35CC43D7-12C5-4F9A-AE76-EB4269CDC038Q47655536-A5CF70C7-0200-4275-B042-AD62213312EDQ47886005-7F7FDD29-5AFC-4D3A-8980-D00BF4AC5B1AQ47936570-DCB0710E-A343-4986-9B89-4105FC24B83DQ48072301-F2109D3B-1670-4C44-9277-B191E7B2376CQ51758956-42B948D1-7C06-456F-A7A7-C469E05AFBB9Q52567779-D3C11C1B-FD52-4603-A12D-7F40962DFC8AQ55437766-ABF02AA1-56FF-4D70-BAE9-528BB4478F21Q59432680-D4E5F345-2673-4A6B-9100-E680F79F29FFQ61810727-1EF88D3C-2E2D-4C66-B3DC-68AB06683BACQ64135041-56E8C800-D8DE-4A13-B981-56A81F2BC728Q64135045-5E2EF8E5-3320-4C8D-B585-E2A284A876DAQ64135047-2C1E7762-DC63-46C6-9474-D9D2CB8FCF9BQ64135050-276066DC-BE81-4768-8B12-3F340D68B69AQ64135053-0342313F-7533-450D-B37C-782B4A54AE2EQ64135058-4FAFB77F-B34A-45DC-94BA-E9A9D671CE16
P50
description
onderzoeker
@nl
researcher ORCID ID = 0000-0003-2368-2262
@en
name
Job F.M. van Boven
@ast
Job F.M. van Boven
@en
Job F.M. van Boven
@es
Job F.M. van Boven
@nl
type
label
Job F.M. van Boven
@ast
Job F.M. van Boven
@en
Job F.M. van Boven
@es
Job F.M. van Boven
@nl
prefLabel
Job F.M. van Boven
@ast
Job F.M. van Boven
@en
Job F.M. van Boven
@es
Job F.M. van Boven
@nl
P106
P1153
53464198500
P21
P31
P496
0000-0003-2368-2262